Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M17qZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfjTWM2OD1yLkC2NUDPxE1? M4O2SXNCVkeHUh?=
ALL-PO NXP6NYpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H2eGlEPTB;MD6wOlM2PSEQvF2= MmPaV2FPT0WU
697 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\nd2lEPTB;MD6wPVk4PiEQvF2= M3;UNnNCVkeHUh?=
NCI-H748 M1TkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPY[HZ{UUN3ME2wMlExOzN2IN88US=> MV;TRW5ITVJ?
NKM-1 M1[5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnCdnlKSzVyPUCuNVA6OTJizszN NE\2T4NUSU6JRWK=
ES1 MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:1[GlEPTB;MD6xNVI2PSEQvF2= NHvofZZUSU6JRWK=
NCI-H1963 M2PYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLrS3J6UUN3ME2wMlEyPTd7IN88US=> NUjFUWNQW0GQR1XS
NCI-H1417 NUTDXHJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr3cm9KSzVyPUCuNVI6PzRizszN NGDSUoFUSU6JRWK=
NEC8 M3;scWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTwTWM2OD1yLkGzOVI4KM7:TR?= M4\DSXNCVkeHUh?=
CRO-AP2 MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fHWWlEPTB;MD6xOlg5QSEQvF2= Ml3DV2FPT0WU
A3-KAW MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\ReGlEPTB;MD6xO|YzPyEQvF2= M{LBU3NCVkeHUh?=
SF539 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIroUXJKSzVyPUCuNVk2QTNizszN NF60UGdUSU6JRWK=
NOS-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jDcmlEPTB;MD6xPVYyQSEQvF2= NIj1O|JUSU6JRWK=
NTERA-S-cl-D1 NVjRT4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrNTWM2OD1yLkKwNVE{KM7:TR?= MkP1V2FPT0WU
COR-L88 NWX1eHFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nSfmlEPTB;MD6yNlk2QSEQvF2= NUnCPXhPW0GQR1XS
EM-2 MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PQUWlEPTB;MD6yOFA4QSEQvF2= NUfsbYF1W0GQR1XS
KARPAS-45 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXQ[GFoUUN3ME2wMlI4QDN|IN88US=> NVnIboVlW0GQR1XS
DSH1 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpTWlEPTB;MD6yPFcxQCEQvF2= NUjPSm9tW0GQR1XS
HT-144 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwM{CyOVYh|ryP NUfkO2dFW0GQR1XS
ATN-1 M4Hvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrDWFJKSzVyPUCuN|A2PzZizszN M3r0XHNCVkeHUh?=
HEL NVfyVmNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPTTWM2OD1yLkOxN|Q5KM7:TR?= NF7L[YtUSU6JRWK=
NB12 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW1VG5yUUN3ME2wMlMyPzV4IN88US=> NWP6WHNLW0GQR1XS
LU-139 M4PUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPFTWM2OD1yLkOzOVEh|ryP M4CwS3NCVkeHUh?=
J-RT3-T3-5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy2bFlKSzVyPUCuN|M4OTZizszN Mnv5V2FPT0WU
MOLT-13 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TxNGlEPTB;MD6zN|gyKM7:TR?= NEjPT5lUSU6JRWK=
SR MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwM{SyOlEh|ryP M1m1dXNCVkeHUh?=
CMK M4nZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fjbGlEPTB;MD6zOVczPyEQvF2= M1y1cHNCVkeHUh?=
ES8 M4rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uzZWlEPTB;MD6zOlAzOiEQvF2= MYPTRW5ITVJ?
LB647-SCLC MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrEbI9KSzVyPUCuN|Y4OyEQvF2= NX\jZXNPW0GQR1XS
TE-8 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{[5N|Uh|ryP NGjRNIJUSU6JRWK=
BV-173 NE[xZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwM{exNlEh|ryP MXrTRW5ITVJ?
DEL MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwM{e0PFch|ryP M1nE[3NCVkeHUh?=
ARH-77 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwM{ixPVMh|ryP M3j1dHNCVkeHUh?=
NCCIT M1vIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTlTWM2OD1yLkO4OlQ6KM7:TR?= NV[4VZJWW0GQR1XS
RPMI-8402 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwM{i3NFEh|ryP M3LBbXNCVkeHUh?=
MONO-MAC-6 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC4TWM2OD1yLkO4O|c3KM7:TR?= MX\TRW5ITVJ?
SK-MM-2 NGDRc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwM{m4Olgh|ryP NGjaRolUSU6JRWK=
CHP-126 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDYR5JnUUN3ME2wMlQxOjNzIN88US=> MknUV2FPT0WU
A101D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNECzJO69VQ>? MnjCV2FPT0WU
SCH M3LUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jXbGlEPTB;MD60NFM1OiEQvF2= M1njNnNCVkeHUh?=
NMC-G1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3PTWM2OD1yLkSwN|Y4KM7:TR?= MkTZV2FPT0WU
NCI-H209 NXHOZpBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNEC2NVMh|ryP NFT5UpVUSU6JRWK=
MOLT-16 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rtXWlEPTB;MD60NVAyPyEQvF2= M3O5O3NCVkeHUh?=
RPMI-6666 NHX4[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwNEGxNkDPxE1? NGjt[3lUSU6JRWK=
OPM-2 NXG1NG1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnGbnFtUUN3ME2wMlQyPTF|IN88US=> MlnlV2FPT0WU
MRK-nu-1 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4PZFiUUN3ME2wMlQ{OTV|IN88US=> NGntXIpUSU6JRWK=
BC-1 NX\LSHdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNEO0NFMh|ryP MkjyV2FPT0WU
MHH-NB-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:yTWM2OD1yLkSzOFU{KM7:TR?= NFTKWGNUSU6JRWK=
Ramos-2G6-4C10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwNEO4PVch|ryP MV;TRW5ITVJ?
LS-513 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwNES1NFEh|ryP M3\6UnNCVkeHUh?=
K5 M1PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C1VWlEPTB;MD60O|AzPSEQvF2= NITjTFhUSU6JRWK=
HOP-62 M{LvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwNEizOVgh|ryP MnHSV2FPT0WU
NCI-H187 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonFTWM2OD1yLkS5NlI4KM7:TR?= NYLySWlMW0GQR1XS
BE-13 NHnHXlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNEm2OlEh|ryP NVnXbnd[W0GQR1XS
HC-1 NVzmcIxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDZemQyUUN3ME2wMlUxPDd|IN88US=> Moq1V2FPT0WU
ACN MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD1TWM2OD1yLkWxNFI5KM7:TR?= MoO3V2FPT0WU
HCC1599 NF3pcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPYTWM2OD1yLkWxOVch|ryP M1LxO3NCVkeHUh?=
MV-4-11 MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTxTWM2OD1yLkWzNFQyKM7:TR?= M4f1b3NCVkeHUh?=
LC-2-ad M3\sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[zTWM2OD1yLkWzOlY{KM7:TR?= MkPTV2FPT0WU
HL-60 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXmTWM2OD1yLkW0NlYyKM7:TR?= NWDUNFBqW0GQR1XS
NB17 NYi3S3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnzTWM2OD1yLkW0N|gh|ryP M3\rXnNCVkeHUh?=
TE-1 NVvF[21rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\GN2tXUUN3ME2wMlU2OzB4IN88US=> M{LYOXNCVkeHUh?=
NCI-H524 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W1cWlEPTB;MD61OVQxOSEQvF2= NH[1UFlUSU6JRWK=
MZ7-mel MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHydJRKSzVyPUCuOVYyODVizszN NGTZVnJUSU6JRWK=
L-363 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[xRnNGUUN3ME2wMlU3PjV5IN88US=> NGrwUm9USU6JRWK=
BL-41 NITaOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzoVpZKSzVyPUCuOVY5QDlizszN M2HLdXNCVkeHUh?=
LU-134-A M{j0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XMO2lEPTB;MD61O|A4OyEQvF2= NYP3eHV2W0GQR1XS
SIG-M5 M3T0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD1yLkW3PFQ5KM7:TR?= M1fLO3NCVkeHUh?=
ONS-76 NVHhVGoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\nSGlEPTB;MD61PFI1OiEQvF2= NX3GT45RW0GQR1XS
KARPAS-299 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrFOJZEUUN3ME2wMlU5PTB2IN88US=> NGrlTmhUSU6JRWK=
DU-4475 NXzNTYRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjZTWM2OD1yLkW4O|A{KM7:TR?= NX\jemdmW0GQR1XS
NB69 M1XD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\S[GE6UUN3ME2wMlU6QDJ3IN88US=> Moq2V2FPT0WU
MHH-PREB-1 M4HufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNkC3NVkh|ryP MVHTRW5ITVJ?
LU-165 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP2SZBKSzVyPUCuOlE5OTJizszN NFjw[WlUSU6JRWK=
LOUCY MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNkOzOlQh|ryP NXfBdWZRW0GQR1XS
NCI-H526 M3T4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme2TWM2OD1yLk[zOVQyKM7:TR?= NFXkbplUSU6JRWK=
KE-37 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNkSyO|Yh|ryP MofaV2FPT0WU
NALM-6 NXH0WllDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjCTWM2OD1yLk[0PFYh|ryP NXm0V3FzW0GQR1XS
CW-2 NYHMPZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PSNGlEPTB;MD62OVc6PCEQvF2= M3;BW3NCVkeHUh?=
SU-DHL-1 NUflR2RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jBOWlEPTB;MD62OVk1PyEQvF2= NGD1RlFUSU6JRWK=
NB13 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjWWXFXUUN3ME2wMlY3QDF5IN88US=> NYXHb3Z6W0GQR1XS
QIMR-WIL NXywVI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjpSW5JUUN3ME2wMlY5OzR|IN88US=> NIHSZmlUSU6JRWK=
ECC12 M2LxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwN{CwPFYh|ryP NGXibpdUSU6JRWK=
KALS-1 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L3V2lEPTB;MD63NFQ6OiEQvF2= NGfBdZZUSU6JRWK=
COR-L279 NYHlUJU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwN{C5PVYh|ryP NW\zV5d1W0GQR1XS
NB14 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fEbGlEPTB;MD63NlYyPyEQvF2= NUD4NYsxW0GQR1XS
CCRF-CEM NGXtfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;TS4loUUN3ME2wMlc1PjZzIN88US=> MmK0V2FPT0WU
SW954 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmSWlEPTB;MD63OVk6QSEQvF2= M{iwNnNCVkeHUh?=
IST-SL1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPUWGRHUUN3ME2wMlc4OzR6IN88US=> NVfnOm5GW0GQR1XS
LAMA-84 M2HYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwN{e1Olch|ryP MV7TRW5ITVJ?
Daudi MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrMXmVKSzVyPUCuO|c3QDFizszN NYD3Oo1{W0GQR1XS
BC-3 NUfvNmdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH25XmpKSzVyPUCuO|g{ODhizszN NYPxRnAyW0GQR1XS
HCC2998 M2C5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPXTWM2OD1yLke4N|Yh|ryP NGjqfHVUSU6JRWK=
NCI-H69 NIG2eoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHezU4tKSzVyPUCuPFAyPDdizszN M2q2R3NCVkeHUh?=
CPC-N MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwOEC1NlQh|ryP NGnxWYJUSU6JRWK=
NOMO-1 NXXCfnhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwOEGwPFQh|ryP Mny2V2FPT0WU
CESS MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfvTWM2OD1yLkixNVk4KM7:TR?= Ml;LV2FPT0WU
LC4-1 M{PUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;WcopKSzVyPUCuPFQxODdizszN NXvaZ3JvW0GQR1XS
BL-70 M3nlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1S0UmlEPTB;MD64OVcxOiEQvF2= MXzTRW5ITVJ?
ES4 NEG1RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3HTWM2OD1yLki1PFY5KM7:TR?= NEDxdGRUSU6JRWK=
HCE-T MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPSRZBKSzVyPUCuPFcyPzFizszN M2\IWnNCVkeHUh?=
JAR NXe2SpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC1N5lyUUN3ME2wMlg4QDJ5IN88US=> M3y5NnNCVkeHUh?=
ST486 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jvVGlEPTB;MD64O|kyPyEQvF2= NVzaN25zW0GQR1XS
KS-1 M4ix[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvIWIoxUUN3ME2wMlg5ODl4IN88US=> NYnUV|RCW0GQR1XS
GDM-1 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L5cWlEPTB;MD64PFY5PyEQvF2= NVz4[ZhYW0GQR1XS
EHEB NInSTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml22TWM2OD1yLkmyOVg2KM7:TR?= MXHTRW5ITVJ?
LB2518-MEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnIcZFmUUN3ME2wMlk{Ojh2IN88US=> MYnTRW5ITVJ?
GOTO MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXiNJVIUUN3ME2wMlk2ODd4IN88US=> NVz3ZXlbW0GQR1XS
LXF-289 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHizb4dKSzVyPUCuPVU6ODFizszN NHfzd2lUSU6JRWK=
ES6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwOU[0N|ch|ryP MXvTRW5ITVJ?
OS-RC-2 M4jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rMeWlEPTB;MD65Olg{KM7:TR?= M4DOTnNCVkeHUh?=
DMS-153 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwOUe0Olkh|ryP M2jxZXNCVkeHUh?=
SK-PN-DW MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH22T5NKSzVyPUCuPVc5OzFizszN NWOxTYxpW0GQR1XS
HH NIjvUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e4fWlEPTB;MD65PFk2QSEQvF2= MXTTRW5ITVJ?
SH-4 MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj6OmVKSzVyPUGuNFI1OSEQvF2= NXLVcI02W0GQR1XS
MOLT-4 NEfmbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXueFR4UUN3ME2xMlA{PDV2IN88US=> M3zPbXNCVkeHUh?=
TGW NGfsSpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XnUmlEPTB;MT6wO|Y4PSEQvF2= M4rt[XNCVkeHUh?=
L-540 M1\a[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPWdJlKSzVyPUGuNVA3ODRizszN NVO3dVh7W0GQR1XS
PF-382 Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[yTWM2OD1zLkGxOVE{KM7:TR?= M2fxNHNCVkeHUh?=
LC-1F NEHOdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH5eFdDUUN3ME2xMlEzODB5IN88US=> NXfWT4ZjW0GQR1XS
OVCAR-4 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwMUOxOlUh|ryP NH\sNnFUSU6JRWK=
A4-Fuk M1TXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXwc5ZkUUN3ME2xMlE2OzZ2IN88US=> M4HmfHNCVkeHUh?=
HCC2218 NVzlZ4dKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET2OXRKSzVyPUGuNVY3PDFizszN MYjTRW5ITVJ?
HAL-01 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMU[5OFMh|ryP NHrtZppUSU6JRWK=
IST-MEL1 M4mwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vjSWlEPTB;MT6xO|Y2QSEQvF2= MY\TRW5ITVJ?
NCI-H719 NY\yVHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXsPWRKSzVyPUGuNVc5QThizszN MXrTRW5ITVJ?
EVSA-T NH;aXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jBZmlEPTB;MT6xPFEyPCEQvF2= MlTwV2FPT0WU
SK-NEP-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISzWmlKSzVyPUGuNlAzPjZizszN NIDSSFdUSU6JRWK=
OCUB-M NVzCd25OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLpW|M6UUN3ME2xMlIyPDh7IN88US=> NXjKVoVJW0GQR1XS
MEG-01 NXToSFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD3UoJLUUN3ME2xMlIzOTF6IN88US=> M1jucXNCVkeHUh?=
no-10 NYL4[Gc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\iUnV1UUN3ME2xMlI{OTF{IN88US=> M2DUdXNCVkeHUh?=
MHH-CALL-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTSVoI4UUN3ME2xMlI1PzJzIN88US=> Ml7FV2FPT0WU
SK-N-DZ M2fGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwMkS3O|Yh|ryP NGqxSWhUSU6JRWK=
SCLC-21H NXTWUnYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX6[VI6UUN3ME2xMlI3PDd6IN88US=> NGrD[2dUSU6JRWK=
CTV-1 NX;pboUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXzVG5KSzVyPUGuNlc1OjVizszN MlXlV2FPT0WU
NB1 NF\aZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn4bIFKSzVyPUGuNlc4OzJizszN MmjHV2FPT0WU
NCI-H64 M1nVOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnvTWM2OD1zLkK4OFYzKM7:TR?= M2HJTnNCVkeHUh?=
MDA-MB-134-VI M3;1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7se|lKSzVyPUGuNlg2PzdizszN NYeydFB6W0GQR1XS
LB2241-RCC NX7PeXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn6d3JHUUN3ME2xMlI5PjZ|IN88US=> MULTRW5ITVJ?
8-MG-BA NXnUN4hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nIR2lEPTB;MT6yPFg3PiEQvF2= NYLqSmpIW0GQR1XS
LP-1 NEThNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorXTWM2OD1zLkK5PVQ4KM7:TR?= NX71cHhmW0GQR1XS
LS-411N MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrIVpNKSzVyPUGuN|A6QThizszN Mom5V2FPT0WU
CAL-148 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PlU2lEPTB;MT6zNlU1OiEQvF2= MnXBV2FPT0WU
NCI-H2171 M2nQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwM{S1NFIh|ryP NFHkU3FUSU6JRWK=
JiyoyeP-2003 NXP2fZlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TQZmlEPTB;MT6zOVM6KM7:TR?= MVTTRW5ITVJ?
NCI-H2107 NWjvZph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjrTWM2OD1zLkO1PFg{KM7:TR?= MmS4V2FPT0WU
BB30-HNC NHuzPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH75VXZKSzVyPUGuN|g6PzhizszN NUXINHc1W0GQR1XS
K-562 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fGdWlEPTB;MT6zPVIyQSEQvF2= MUPTRW5ITVJ?
PSN1 NXfaeXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwNEKyPFch|ryP NHHSeZRUSU6JRWK=
HCC2157 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS1TWM2OD1zLkSyOlkyKM7:TR?= MnfkV2FPT0WU
SBC-1 NUG3bmdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnxNGxKSzVyPUGuOFI4PDFizszN NVvSVYVJW0GQR1XS
MC116 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfFdm1UUUN3ME2xMlQ{PjF3IN88US=> NWDmR4UyW0GQR1XS
KARPAS-422 M2fHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PKVWlEPTB;MT60OVM2QCEQvF2= MnS2V2FPT0WU
LB996-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonwTWM2OD1zLkS3NVA{KM7:TR?= NETQbVJUSU6JRWK=
MSTO-211H M1q1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfBN4FEUUN3ME2xMlQ4QTh5IN88US=> MXPTRW5ITVJ?
BT-474 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHxbGhKSzVyPUGuOVE4PjRizszN MVvTRW5ITVJ?
A388 NHHy[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i3fmlEPTB;MT61NVk1PSEQvF2= M4XMWnNCVkeHUh?=
SJSA-1 M{KwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHvTWM2OD1zLkWyNlYh|ryP M2C1ZnNCVkeHUh?=
COLO-829 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfQTWM2OD1zLkWzOVY1KM7:TR?= MlH1V2FPT0WU
KM-H2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPMVFhKSzVyPUGuOVY3PyEQvF2= MWPTRW5ITVJ?
GR-ST NEjWcZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LzemlEPTB;MT61OlgzKM7:TR?= MVvTRW5ITVJ?
RPMI-8866 NGjofFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfvTWM2OD1zLk[wNVQ1KM7:TR?= MknrV2FPT0WU
KG-1 NUDYfVNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Pc3R3UUN3ME2xMlYyQTBzIN88US=> NHfWclZUSU6JRWK=
NCI-H82 Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHNUVZnUUN3ME2xMlY{PDB4IN88US=> MX7TRW5ITVJ?
LB1047-RCC NYDpUZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXkWnhKSzVyPUGuOlM1PTlizszN Ml\2V2FPT0WU
KM12 NHrlT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjyR4czUUN3ME2xMlY1PyEQvF2= MlntV2FPT0WU
NB5 M4nlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTuU49KSzVyPUGuOlU3PzdizszN MUfTRW5ITVJ?
HDLM-2 NFK2UVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTFwNkiyPFEh|ryP NV;jU4k5W0GQR1XS
KU812 NF70OoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1riVWlEPTB;MT62PVYxPSEQvF2= NIfjTpRUSU6JRWK=
DB NH[1cGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwN{CzOVMh|ryP MmXyV2FPT0WU
HD-MY-Z NGfuVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfyXXZKSzVyPUGuO|UzOzRizszN NHT6VHVUSU6JRWK=
KURAMOCHI MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTFwN{eyNFch|ryP MVnTRW5ITVJ?
ETK-1 M2XWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\CTmlEPTB;MT63PFg4QSEQvF2= NUnKSolIW0GQR1XS
SK-UT-1 M4T5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fLd2lEPTB;MT63PVM5QCEQvF2= MmHwV2FPT0WU
HUTU-80 NEjXNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2SGlEPTB;MT63PVUxQCEQvF2= MV3TRW5ITVJ?
ES7 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwOECzNFIh|ryP MUfTRW5ITVJ?
SW872 NVPWdIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInTOnhKSzVyPUGuPFE{QTVizszN MYjTRW5ITVJ?
TK10 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmyTWM2OD1zLkizNVA5KM7:TR?= M4ToR3NCVkeHUh?=
LB831-BLC Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f3W2lEPTB;MT64N|U3OyEQvF2= NXjHRo5LW0GQR1XS
TE-9 NHXwXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwOES0NlIh|ryP MljrV2FPT0WU
MLMA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHWTWM2OD1zLki4NlM1KM7:TR?= M37odHNCVkeHUh?=
D-542MG NFHGWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwOEmzO|Mh|ryP MWTTRW5ITVJ?
EW-16 M1GwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO4bGpLUUN3ME2xMlkzPzJizszN NELEZYVUSU6JRWK=
LOXIMVI M3\iXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwOUOyPEDPxE1? Mm\QV2FPT0WU
GB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq5d5hKSzVyPUGuPVM5PjZizszN NVS4d21DW0GQR1XS
IST-SL2 NFXpUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJwMECyOlIh|ryP NITNNYVUSU6JRWK=
LAN-6 NXuz[W9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrwTWM2OD1{LkCxPVY3KM7:TR?= MkO4V2FPT0WU
NCI-H510A NYLBXFJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJwMES1NFIh|ryP NFPXV2JUSU6JRWK=
NCI-H1092 M2PEWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwMEWxNlQh|ryP M1nOeHNCVkeHUh?=
HT MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV75TpZMUUN3ME2yMlExPDV2IN88US=> NYnPNWxoW0GQR1XS
RL95-2 NITxOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XNOmlEPTB;Mj6xNVQ5OiEQvF2= NWj6VpFFW0GQR1XS
NCI-H1355 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJwMUG3PVIh|ryP MYLTRW5ITVJ?
NCI-H720 NYn1XZZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEWyfFlKSzVyPUKuNVY5PzNizszN NF3POI9USU6JRWK=
NCI-H1522 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDYTXdnUUN3ME2yMlIyPzJ|IN88US=> NUnqfZlIW0GQR1XS
LB373-MEL-D NUPvSpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7HTWM2OD1{LkK2PVAzKM7:TR?= MlvtV2FPT0WU
DG-75 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[2XHZKSzVyPUKuNlcyPDhizszN NXjKbnhVW0GQR1XS
ML-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDTN3ZKSzVyPUKuN|I5PTVizszN NWTKSWFYW0GQR1XS
SF126 NH;qfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHmTWM2OD1{LkOzNFk1KM7:TR?= M1rlVXNCVkeHUh?=
MPP-89 NVHkNopST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;kXY9bUUN3ME2yMlM{OTR3IN88US=> MYnTRW5ITVJ?
NCI-H345 NGTkSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfSbJdUUUN3ME2yMlM{Ojd5IN88US=> MUPTRW5ITVJ?
LS-123 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJwM{S5N|Yh|ryP NWG5VGg1W0GQR1XS
NB10 NUCwSnptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrFUJhKSzVyPUKuOFExQTJizszN MkjyV2FPT0WU
CGTH-W-1 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPjeJhmUUN3ME2yMlQzOjZ5IN88US=> MX\TRW5ITVJ?
CP66-MEL M2HrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;GTWM2OD1{LkS3O|ch|ryP NGftZpZUSU6JRWK=
L-428 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jSSmlEPTB;Mj60PFUzOSEQvF2= Ml[yV2FPT0WU
DMS-79 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr0ZmtKSzVyPUKuOVQyODNizszN M4L6S3NCVkeHUh?=
NCI-H1882 NIHBeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwNke1OlIh|ryP M3fYPXNCVkeHUh?=
KGN NWXZTJRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HOUGlEPTB;Mj63Olg4PiEQvF2= MV7TRW5ITVJ?
EW-1 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv2WlVKSzVyPUKuO|cxQDNizszN MVPTRW5ITVJ?
U-266 NWDrbYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL4XpNKSzVyPUKuPFQ5OjNizszN MYTTRW5ITVJ?
COLO-320-HSR NY\kU3I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWzTWM2OD1{Lki1OlQyKM7:TR?= M1;NR3NCVkeHUh?=
KMOE-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfyTWM2OD1{Lki3O|EyKM7:TR?= MlOwV2FPT0WU
BB49-HNC NXPLc4hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrHfJFKSzVyPUKuPVI1QCEQvF2= MXzTRW5ITVJ?
GI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[xTWM2OD1{LkmyPVU4KM7:TR?= M2GwdXNCVkeHUh?=
NCI-H1304 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTNwMEC1NVEh|ryP NFvodGZUSU6JRWK=
NCI-H2227 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOzdoZKSzVyPUOuNFIxPzlizszN MVTTRW5ITVJ?
U-87-MG MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DabGlEPTB;Mz6wN|UyOyEQvF2= Mo\kV2FPT0WU
NCI-H747 NWLF[IxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDTWM2OD1|LkC1NlA3KM7:TR?= M2K1NXNCVkeHUh?=
CTB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNwMEWzO|Yh|ryP NEXwfFNUSU6JRWK=
RPMI-8226 NX\OW3VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrVUm1KSzVyPUOuNVQ{PzhizszN NYLs[5hzW0GQR1XS
NCI-H2141 M1PQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HpRWlEPTB;Mz6xOlU3PiEQvF2= NYjS[WtuW0GQR1XS
IST-MES1 M2XyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HjPWlEPTB;Mz6xPFI4QSEQvF2= MmLBV2FPT0WU
TE-5 M1XZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnsO|F6UUN3ME2zMlIyOzR{IN88US=> MXvTRW5ITVJ?
UACC-257 NGLk[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\pcmlEPTB;Mz60N|Y2QSEQvF2= NYTKc|JoW0GQR1XS
SK-N-FI NY[2OohCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTGTWM2OD1|LkS1NlI4KM7:TR?= MoLhV2FPT0WU
MFH-ino NHfnbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG5bINKSzVyPUOuOFY2QDlizszN MUnTRW5ITVJ?
SF268 NYqwVHd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwNEixO|Qh|ryP MkOwV2FPT0WU
TE-12 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml23TWM2OD1|LkWxOlk6KM7:TR?= NITQbZBUSU6JRWK=
NB6 MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDxV49oUUN3ME2zMlU2PTZ|IN88US=> MVvTRW5ITVJ?
DJM-1 NYS1UlBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;nRWlEPTB;Mz61PVg6QSEQvF2= NX\SXVFNW0GQR1XS
MZ1-PC M{TwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuwcGVtUUN3ME2zMlYyPjJ2IN88US=> MXnTRW5ITVJ?
OCI-AML2 NYTLWVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNwNkK2O|Eh|ryP MU\TRW5ITVJ?
NCI-H1155 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\QTWM2OD1|LkewPVQ4KM7:TR?= NWHCWZRYW0GQR1XS
RKO MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwN{exPFkh|ryP NGnuTGRUSU6JRWK=
ECC4 M4DFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz4OmxKSzVyPUOuPVcyQTVizszN NYDadmpDW0GQR1XS
BB65-RCC NXHYcG5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlepd{UUN3ME2zMlk4PTR5IN88US=> MULTRW5ITVJ?
EB-3 NYLqTmExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7QS2w2UUN3ME2zMlk6PjN|IN88US=> M3PKXXNCVkeHUh?=
SHP-77 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwMEC1NlQh|ryP M2\YO3NCVkeHUh?=
NCI-H2196 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPhTWM2OD12LkC1OlI2KM7:TR?= NGnaVYZUSU6JRWK=
GI-ME-N NYXFXoRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fXd2lEPTB;ND6wOlM6QSEQvF2= NH;3doxUSU6JRWK=
MN-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLSTWM2OD12LkGwPFch|ryP NHL1O49USU6JRWK=
NCI-H1694 M{XIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRwMUO0NFUh|ryP M3f2R3NCVkeHUh?=
LU-65 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfndo4xUUN3ME20MlE2OzN{IN88US=> MlX0V2FPT0WU
NCI-H1436 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;mdGlEPTB;ND6xPFM{OyEQvF2= NH[5WHNUSU6JRWK=
KINGS-1 NIDxWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TNPGlEPTB;ND6zNVQ{OiEQvF2= M2n5U3NCVkeHUh?=
GT3TKB NEn5ZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRwM{OyOlgh|ryP M1TKXHNCVkeHUh?=
Becker Mk\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHZTWM2OD12LkO3N|EzKM7:TR?= MV7TRW5ITVJ?
HCC1187 NEjMSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGqwWWhKSzVyPUSuPFk3PTdizszN NVH0XFVSW0GQR1XS
D-502MG MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXKc|JKSzVyPUWuNFA1OTZizszN MofPV2FPT0WU
VA-ES-BJ Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;nemlEPTB;NT6xN|c4QCEQvF2= MVjTRW5ITVJ?
NB7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfQRo1KSzVyPUWuNVQyOTJizszN M4HMWXNCVkeHUh?=
SW962 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfmTWM2OD13LkO4PFE1KM7:TR?= MUXTRW5ITVJ?
no-11 NVfTe4VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorpTWM2OD13Lke2N|Q{KM7:TR?= NXfRcpV1W0GQR1XS
KNS-81-FD MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTVwOUC2PVQh|ryP NYezN4F6W0GQR1XS
COLO-684 M4H2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K0TWlEPTB;NT65PVQ6PCEQvF2= NEm2c25USU6JRWK=
D-263MG NU\4NWRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrQSWtKSzVyPU[uNFg5QTVizszN NWPFe2VZW0GQR1XS
EW-24 MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnPTWM2OD14LkK4OVEh|ryP MUfTRW5ITVJ?
TE-10 MoTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrvNINKSzVyPU[uOFI3OjNizszN NGnxWG5USU6JRWK=
EKVX NHrLZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZwNE[zNlEh|ryP NV7ZUYZLW0GQR1XS
NCI-H1648 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXtdY1FUUN3ME22MlY4PTV5IN88US=> NYjZZWZIW0GQR1XS
LB771-HNC NIPGVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETBc3ZKSzVyPU[uPVI{ODFizszN MX3TRW5ITVJ?
SK-MEL-1 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DSOGlEPTB;OD6xN|E3PiEQvF2= NVPLWI1rW0GQR1XS
COLO-668 NG\odmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\XTWM2OD16LkK3O|g3KM7:TR?= NYX4cldYW0GQR1XS
EW-12 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofDTWM2OD16LkSwPFA{KM7:TR?= NIXnWWxUSU6JRWK=
A253 NHPOSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;NTWM2OD16Lki0OlYyKM7:TR?= MojJV2FPT0WU
NCI-H2126 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i5bGlEPTB;OD64PVMyQSEQvF2= M2HsSXNCVkeHUh?=
Calu-6 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRThwOUmwOFIh|ryP M1XQ[XNCVkeHUh?=
NCI-H23 NHP0eXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTlwMUe3OFYh|ryP MVjTRW5ITVJ?
WSU-NHL NHS3Z3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF71e45KSzVyPUmuO|c1PzhizszN NIrZflNUSU6JRWK=
MMAC-SF Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TLeWlEPTB;OT65O|kxPCEQvF2= Ml7vV2FPT0WU
SK-LMS-1 NYjSTlVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFyLkK4N|Qh|ryP MoK1V2FPT0WU
GCIY MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPsTWM2OD1zMD61PVI1KM7:TR?= M4n2THNCVkeHUh?=
TE-15 M1PaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPrVIRKUUN3ME2xNU43ODB2IN88US=> MYnTRW5ITVJ?
EoL-1-cell NETISG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:wTWM2OD1zMT63OlgzKM7:TR?= NF[3fohUSU6JRWK=
NCI-H2081 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFzLke3PFYh|ryP NXv2dnQ3W0GQR1XS
EW-3 M2T3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF{LkK0OlMh|ryP M2\vUnNCVkeHUh?=
CAS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPwfFNKSzVyPUGyMlM3OzFizszN NULVRmFJW0GQR1XS
C2BBe1 NHHqVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GwXWlEPTB;MUKuOlE{OSEQvF2= NG\IUVlUSU6JRWK=
D-247MG NVzPRYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTF{Lke5OVIh|ryP MnfrV2FPT0WU
NCI-SNU-5 M{\KeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPERoxKSzVyPUGyMlgxOTNizszN NH;GVpJUSU6JRWK=
LS-1034 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TQO2lEPTB;MUSuN|k4PSEQvF2= Mnv1V2FPT0WU
EW-18 M3;aO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWzfGZzUUN3ME2xOE41PDhizszN NGOzSY5USU6JRWK=
Raji M3Ppb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDOTWM2OD1zND61NFQ6KM7:TR?= MWXTRW5ITVJ?
D-283MED M1TsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF2Lk[yO|Eh|ryP MljIV2FPT0WU
MZ2-MEL NWHsXYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjTWM2OD1zND65Olk3KM7:TR?= NYO2V4UxW0GQR1XS
NCI-SNU-16 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW4NYFsUUN3ME2xOU41PjN|IN88US=> MoDXV2FPT0WU
P30-OHK MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXKbJVKSzVyPUG3Mlc5OzFizszN NYLCbodRW0GQR1XS
RXF393 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\RbmpKSzVyPUG5MlAyQDZizszN NFPLN4ZUSU6JRWK=
NCI-H1395 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJyLk[3NFMh|ryP MWTTRW5ITVJ?
U-698-M M3\4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLNTWM2OD1{MD63NFc2KM7:TR?= NYj0NGN{W0GQR1XS
NCI-SNU-1 NHzXSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJyLkeyNlMh|ryP M{jUPHNCVkeHUh?=
SW684 NYDx[3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTETWM2OD1{MT6xO|E3KM7:TR?= NWrEb4Z4W0GQR1XS
NCI-H716 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmyTWM2OD1{MT6zNVU1KM7:TR?= MWXTRW5ITVJ?
JVM-2 NFjWNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HieGlEPTB;MkGuOFE{OyEQvF2= M4rVW3NCVkeHUh?=
NCI-H1581 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH1VWp2UUN3ME2yNk41OTR6IN88US=> M4PEcXNCVkeHUh?=
CA46 NW\vZ4VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i5VmlEPTB;M{GuOlk{PiEQvF2= M361dHNCVkeHUh?=
SNB75 NVvsZY5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LzdmlEPTB;M{OuOlUxOyEQvF2= MYDTRW5ITVJ?
KNS-42 NVXzVpVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN3Lkm2NlQh|ryP MWrTRW5ITVJ?
TUR NIrON25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN4LkC1NlEh|ryP M4PHR3NCVkeHUh?=
REH NVnVcllWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEG0eJBKSzVyPUO3MlgzOTFizszN Ml\RV2FPT0WU
EW-22 M1nMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qwTWlEPTB;NEKuNlg5PSEQvF2= M1jsPXNCVkeHUh?=
NCI-H446 NFXyZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX4eYdpUUN3ME20Nk44QDV|IN88US=> MlrGV2FPT0WU
ES3 M3PyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTnUWFbUUN3ME20N{4yOzN7IN88US=> M13NfnNCVkeHUh?=
EW-11 NYKzU|kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\n[mlEPTB;NESuPFIyQCEQvF2= MVnTRW5ITVJ?
RH-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\rTWM2OD12Nz61PFEzKM7:TR?= NXTiblM5W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID